Facing the loss of patent protection and profits on top-selling brands, drugmakers sometimes stop or sharply limit sales of drugs to force consumers to switch to a somewhat modified, newly patented version before generic rivals have a chance to get into the market. Jerry Avorn, professor of medicine at Brigham and Women’s Hospital, is quoted.
